San Diego, CA, October 7, 202 ...
Sisu Pharma Welcomes Renowned Prostate Cancer Drug Developer Professor Michael Jung to its Scientific Advisory Board
Sisu Pharma, a biotech company exploiting cellular stress to treat therapy-resistant cancers, is delighted to announce that Professor Michael Jung has joined its Scientific Advisory Board.
Study Reveals Stress Response Protein’s Critical Role in Leukemia Stem Cell Renewal
A study identified Heat Shock Transcription Factor 1 (HSF1) as a key protein driving the renewal of leukemia stem cells in Acute Myeloid Leukemia (AML). The work is featured in Nature Communications Cancer Highlights.
Breakthrough Study Shows Potential New Treatment for Therapy-Resistant Prostate Cancer
A new study published in the journal Science Translational Medicine has revealed a potential breakthrough in the treatment of therapy-resistant prostate cancer.
